Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P030016/S048

VISIAN ICL (IMPLANTABLE COLLAMER LENS)

STAAR Surgical Company · Decision date Nov 14, 2025

FDA DECISIONP030016/S048

What did the FDA approve?

FDA records P030016/S048 as a supplement to PMA P030016, with the supplement type “Normal 180 Day Track”. The recorded decision is approval, dated Nov 14, 2025.

FDA approval order statement

approval for expanding the indicated age range from 21-45 years old to 21-60 years old for the EVO/EVO+ ICL/TICL.
Regulatory pathway
PMA supplement
Supplement type
Normal 180 Day Track
Clinical specialty
Ophthalmic
Decision date
Nov 14, 2025
FDA change category
Labeling Change - Indications/instructions/shelf life/tradename

FDA source record

Regulatory record facts

Identifier
P030016/S048
Regulatory pathway
PMA supplement
Product code
MTA
Decision code
APPR
Decision date
Nov 14, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Lens, intraocular, phakic.

Product code
MTA
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P030016/S048 received

    Application receipt date recorded by FDA.

  2. P030016/S048 · FDA decision

    Normal 180 Day Track

  3. P030016/S049 · Related supplement

    Visian Toric Implantable Collamer Lens (TICL)

  4. P030016/S051 · Related supplement

    The EVO/EVO+ Visian Implantable Collamer Lens (ICL)

Timeline entries are records held by MedtechLedger for P030016. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P030016

Product / regulatory recordCompanyPathwayDecision dateSource
STAAR Surgical CompanyPMA supplementDec 10, 2025FDA
STAAR Surgical CompanyPMA supplementMar 4, 2026FDA

Explore the linked device profile

Other records with product code MTA

Product / regulatory recordCompanyPathwayDecision dateSource
Ophtec BVPMA supplementApr 24, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

STAAR Surgical Company

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
1911 Walker Ave., Monrovia, CA, 91016

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records